BMI Thresholds: A Global vs. Local Issue
The recent introduction of generic semaglutide in India brings with it a crucial discussion point: the applicability of established international guidelines.
A pivotal study, the SELECT trial, involving 17,604 participants and published in The New England Journal of Medicine in 2023, demonstrated that a weekly dose of semaglutide was effective in reducing major cardiovascular events by 20%. This positive outcome was observed in adults with a Body Mass Index (BMI) of 27 or higher who had pre-existing cardiovascular conditions but did not have diabetes. The trial meticulously tracked these individuals for almost 40 months. However, experts like Aditi Kantipuly, a resident in preventive medicine and public health at McGill University and a visiting scholar at the University of New Mexico, are highlighting a potential pitfall. Applying the same 27 BMI threshold in India could inadvertently disqualify a substantial portion of the population who are at high risk for cardiovascular issues, despite potentially having a lower BMI than specified in the global trial criteria. This raises questions about the universality of such thresholds and the necessity for context-specific adaptations.
SELECT Trial Findings & Indian Context
The SELECT trial, a significant clinical investigation led by A. Michael Lincoff, provided compelling evidence for the cardiovascular benefits of semaglutide. Its findings, published in The New England Journal of Medicine in 2023, revealed that adults with a BMI of 27 or above, coupled with established cardiovascular disease but without diabetes, experienced a 20% reduction in major cardiovascular events when treated with once-weekly semaglutide. This large-scale study involved 17,604 participants and monitored their health outcomes over a period of nearly 40 months. While these results are groundbreaking, their direct translation to the Indian demographic is being questioned. Preventive medicine specialist Aditi Kantipuly points out that the prevalent body composition and health profiles in India may differ significantly. A BMI of 27 might represent a different level of health risk in an Indian individual compared to someone from a Western population, potentially meaning that individuals with a BMI below this threshold in India could still be at considerable cardiovascular risk and would therefore be excluded from the benefits of semaglutide if the global guidelines are strictly adhered to. This discrepancy necessitates a closer examination of how these medications are recommended for use within the Indian healthcare system.
